Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

What happened: Zealand Pharma reported positive topline results from the multiple ascending dose part of its Phase 1 trial of ZP9830, a Kv1.3 ion channel blocker, in 32 healthy participants. Key numbers: 32 healthy participants; 4-week treatment duration; safety follow-up until day 41; Phase 1b trial in plaque psoriasis recently initiated; Phase 2 trial in an additional autoimmune Why it matters: Multiple doses were well tolerated with no serious or severe adverse events or dose-limiting safety findings, and the company said the PK data support continued development in longer trials. Market: -0.9% today ($224.20), -51.3% YTD, 0.1x vol — as of 07:45 UTC

Zealand Pharma reported positive topline results from the multiple ascending dose part of its Phase 1 trial of ZP9830, a Kv1.3 ion channel blocker, in 32 healthy participants.

Multiple doses were well tolerated with no serious or severe adverse events or dose-limiting safety findings, and the company said the PK data support continued development in longer trials. Market: -0.9% today ($224.20), -51.3% YTD, 0.1x vol — as of 07:45 UTC